





Native PAGE immunoblot  
(uncropped)  
anti-proteasome



Protein loading  
(india ink stain)







Supplemental Figure 2:

H<sub>2</sub>O<sub>2</sub> stress survival assay RU486 controls for Figures 1E and 2F. RU486 treatment produces minimal changes to oxidative stress under control of the drivers Da-GS-GAL4 and Elav>GS-GAL4. Flies were fed 4.4M H<sub>2</sub>O<sub>2</sub> mixed with 5% sucrose, survival was monitored every 8 hr, N = 75. Flies were removed from RU486 during stress assay to prevent potential differences in consumption.

	- RU486	+ RU486	%	Chi-Square	Logrank
DA-GS-GAL4>UAS-Prosβ5 N ≈ 200					
Median (50%)	75.4	75.3	-0.2	2.5	0.11
Maximum (10%)	87.1	84.9	-2.6		
Tub5-GS-GAL4>UAS-Prosβ5 N ≈ 250					
Median (50%)	66.0	66.5	0.8	0.2	0.64
Maximum (10%)	74.7	73.7	-1.3		

Supplemental Figure 3:  
Lifespan statistics for Figures 1F-G.





Supplemental Figure 4:  
Lifespan RU486 controls for Figure 1F-G.

	Elav-GS-GAL4>UAS-Prosβ5				
	- RU486	+ RU486	%	Chi-Square	Logrank
Lifespan 1 N ≈ 250					
Median (50%)	77.4	86.5	11.9	66	4.44x10 <sup>-16</sup>
Maximum (10%)	89.1	98.4	10.4		
Lifespan 2 N ≈ 175					
Median (50%)	63.3	68.7	8.5	77.8	<1x10 <sup>-18</sup>
Maximum (10%)	68.7	77.6	12.9		
Lifespan 3 N ≈ 225					
Median (50%)	67.0	77.8	16.1	176	<1x10 <sup>-18</sup>
Maximum (10%)	70.0	85.3	21.7		
Lifespan 4 N ≈ 250					
Median (50%)	83.9	88.9	5.9	22.6	2.03x10 <sup>-6</sup>
Maximum (10%)	93.1	99.2	6.5		

	Elav-GS-GAL4>W <sup>1118</sup>				
	- RU486	+ RU486	%	Chi-Square	Logrank
Lifespan 1 N ≈ 175					
Median (50%)	98.0	97.3	-0.7	2.4	0.12
Maximum (10%)	104.5	104.4	-0.2		
Lifespan 2 N ≈ 175					
Median (50%)	85.5	86.6	1.2	77.8	0.04
Maximum (10%)	92.2	95.6	3.6		

Supplemental Figure 5:  
Lifespan statistics for Figures 2A-B.

**A****B**

Supplemental Figure 6:

A. RU486-induced Prosβ5 overexpression increases under control of the Elav-GS-GAL4 (Elav-GS-GAL4>Prosβ5) driver increases 20S proteasome based on an Suc-LLVY-AMC activity assay. No increase in activity seen in flies lacking the transgene (Elav-GS-GAL4>W<sup>1118</sup>), N = 12. **B.** RU486 treatment does not alter behavior in olfaction aversion training. Assay performed in 10 day old Elav-GS-GAL4>W<sup>1118</sup> flies, N = 150.